Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

Early Phase 1

Recruiting

Conditions: Resectable Hepatocellular Carcinoma
Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Radiation: Stereotactic Beam Radiation Therapy (SBRT)

First Posted Date: 2021-04-23

Last Posted Date: 2024-08-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT04857684

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Paclitaxel

First Posted Date: 2021-04-06

Last Posted Date: 2024-11-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT04832854

Locations: 🇨🇭
Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland
🇨🇭
UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland
🇦🇺
Cabrini Hospital Malvern, Malvern, Victoria, Australia

and more 21 locations

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Phase 2

Active, not recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2021-04-02

Last Posted Date: 2024-01-11

Lead Sponsor: Howard S Hochster

Target Recruit Count: 50

Registration Number: NCT04829383

Locations: 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
DHR Health Institute for Research and Development, Edinburg, Texas, United States

and more 4 locations

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Phase 2

Recruiting

Conditions: Cancer Metastatic

Interventions: Drug: Atezolizumab

First Posted Date: 2021-03-26

Last Posted Date: 2024-02-29

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 3000

Registration Number: NCT04817956

Locations: 🇳🇴
Sykehuset Vestfold, Tønsberg, Norway
🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇴
Sykehuset Innlandet, Hamar, Norway

and more 14 locations

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone Acetate 250mg
Drug: Apalutamide 60mg Tab
Drug: Atezolizumab
Drug: Prednisone 5mg Tab
Drug: Niraparib 100mg Oral Capsule
Drug: Docetaxel

First Posted Date: 2021-03-23

Last Posted Date: 2024-12-16

Lead Sponsor: University of British Columbia

Target Recruit Count: 315

Registration Number: NCT04812366

Locations: 🇺🇸
University of California Davis, Sacramento, California, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
University of Michigan Health, Ann Arbor, Michigan, United States

and more 6 locations

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Phase 3

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: TACE
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2021-03-18

Last Posted Date: 2024-04-04

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 434

Registration Number: NCT04803994

Locations: 🇦🇹
Medzinische Universität Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinikum Bochum, Bochum, Germany
🇩🇪
Vivantes Klinikum Neukölln, Berlin, Germany

and more 65 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1

Recruiting

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Interventions: Drug: Giredestrant
Drug: Ribociclib
Drug: PH FDC SC
Drug: Abemaciclib
Drug: Ipatasertib
Drug: Inavolisib
Drug: Samuraciclib
Drug: Everolimus
Drug: Atezolizumab
Drug: Palbociclib

First Posted Date: 2021-03-17

Last Posted Date: 2024-12-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 510

Registration Number: NCT04802759

Locations: 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸
Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 25 locations

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Not Applicable

Terminated

Conditions: Cancer

Interventions: Drug: Trametinib
Drug: Cobimetinib
Drug: Binimetinib
Drug: Alpelisib
Drug: Vemurafenib
Drug: Dabrafenib
Drug: Encorafenib
Drug: Palbociclib
Drug: Olaparib
Drug: Ribociclib
Drug: Abemaciclib
Drug: Talazoparib
Drug: Nivolumab
Drug: Atezolizumab
Drug: Pembrolizumab

First Posted Date: 2021-03-17

Last Posted Date: 2023-05-10

Lead Sponsor: Peter MacCallum Cancer Centre, Australia

Target Recruit Count: 3

Registration Number: NCT04801966

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Phase 1

Recruiting

Conditions: Rhabdomyosarcoma
Solid Tumor

Interventions: Drug: Atezolizumab
Drug: Vincristine
Drug: Irinotecan
Drug: Temozolomide

First Posted Date: 2021-03-12

Last Posted Date: 2024-06-12

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 23

Registration Number: NCT04796012

Locations: 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States

and more 4 locations

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Diseases
Stage IIIA Non-small Cell Lung Cancer
Respiratory Tract Neoplasms
Stage IIIB Non-small Cell Lung Cancer
Carcinoma Bronchiogenic Stage III
Thoracic Neoplasms

Interventions: Drug: Carboplatin
Drug: Placlitaxel
Drug: Atezolizumab

First Posted Date: 2021-03-01

Last Posted Date: 2024-08-19

Lead Sponsor: Fundación GECP

Target Recruit Count: 38

Registration Number: NCT04776447

Locations: 🇪🇸
Hospital de Basurto, Bilbao, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy